Investigational drug · Phase 3
ABBV-706
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Extensive Stage-Small Cell Lung Cancer (ES-SCLC), Extensive Stage-Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "ABBV-706"
First trial start
2025
Nov 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-706", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer
- Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
- Extensive Stage-Small Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-706" as an intervention, largest first.
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07365241 · 531 participants (planned) · Start Jul 2, 2026 · Primary completion Sep 2030
Drug: ABBV-706; Topotecan and 3 more · For: Small Cell Lung Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Goodyear, Arizona · 72 sites in all
AbbVieAbbVie (ABBV)
NCT05599984 · 288 participants · Start Dec 5, 2022 · Primary completion Nov 2027
Drug: ABBV-706; Cisplatin and 2 more · For: Advanced Solid Tumors
Sites: Gilbert, Arizona; Duarte, California; Irvine, California · 66 sites in all
AbbVieAbbVie (ABBV)
NCT07155174 · 180 participants (planned) · Start Nov 25, 2025 · Primary completion Apr 2029
Drug: ABBV-706; Atezolizumab and 4 more · For: Small Cell Lung Cancer
Sites: New Haven, Connecticut; Gainesville, Florida; Ocala, Florida · 70 sites in all
AbbVieAbbVie (ABBV)
NCT07895056 · 80 participants (planned) · Start Nov 4, 2026 · Primary completion Aug 2031
Drug: ABBV-706; Tarlatamab and 1 more · For: Extensive Stage-Small Cell Lung Cancer
AbbVieAbbVie (ABBV)
NCT07895043 · 80 participants (planned) · Start Nov 20, 2026 · Primary completion Dec 2031
Drug: Alveltamig; Atezolizumab and 1 more · For: Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
- Expanded Access to ABBV-706Available
AbbVieAbbVie (ABBV)
NCT07310277
Drug: ABBV-706 · For: Small Cell Lung Cancer
Newest research
PubMed records naming it or its code names, newest first.
- Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Byers LA, Cho BC, Cooper AJ, et al. · Nat Med 2026
- SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Byers LA, Cho BC, Cooper AJ, et al. · Nat Med 2026
Also in development for Small Cell Lung Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.